Olink® introduces the Target 48 Mouse Cytokine Panel
Olink Holding AB (Uppsala, Sweden) has announced the introduction of the Olink Target 48 Mouse Cytokine panel, a validated multiplexed protein panel for use in cytokine studies and inflammation-related disease research. Offering a detailed view of the murine immune system, the Olink cytokine panel supports in-depth disease modeling, longitudinal studies and translational research.
From pre-clinical mouse models to human clinical applications, Olink provides industry-leading solutions encompassing all stages of drug development and disease modeling. The addition of a targeted mouse panel with absolute quantification capabilities adds to Olink’s broad portfolio of proteomics solutions. The panel allows simultaneous analysis of 45 protein biomarkers using as little as 1µl of biological sample. Offering multiplexing with high specificity and sensitivity, the T48 Mouse Cytokine panel unlocks true longitudinal studies over multiple time points in individual mice.
The technology behind the Olink Target 48 Mouse Cytokine Panel
The Olink panel uses proximity extension assay (PEA) technology to analyze secreted proteins in serum and blood plasma. PEA is a dual recognition approach, matching pairs of antibodies with complementary DNA oligonucleotide tags, which bind to their respective proteins in the sample. When pairs are correctly matched, the oligonucleotides can hybridize and are extended to an amplicon, which has a unique barcode for each protein. This PCR target sequence is then amplified and eventually quantified using next-generation sequencing or qPCR, which generates a digital readout for each protein in the sample.
Jon Heimer, CEO of Olink, commented:
“Olink Target 48 Mouse Cytokine panel gives scientists the ability to go deeper into preclinical and translational disease research, tackling some of the most important and challenging questions in biology. The potential this new product brings to the market is exciting. Requiring minimal sample volume, researchers can gain critical insights into the murine immune system over time, ultimately allowing for more accurate disease modeling and accelerating drug development.”
Cuong Nguyen, Associate Professor, Department of Infectious Diseases and Immunology, University of Florida (FL, USA) described his experience of using the panel:
“We had the privilege of being an early user of the Olink Target 48 Mouse Cytokine panel and were especially impressed with the data produced using our murine samples. What stood out was the remarkable quality of the data it provided. Through its higher multiplexing design, we extracted meaningful results from a comprehensive range of over 40 immune-related biomarkers, all with remarkably minuscule volumes of sera. The sensitivity of the assay undoubtedly sets a new standard. Its performance surpasses other platforms available in the market that we have tried.”
The panel was designed to deliver an in-depth view of cytokine signaling and inflammatory pathways for pre-clinical and translational research and can be utilized across key application areas to deepen the current understanding of molecular pathways involved in disease initiation and progression.
